Literature DB >> 7352752

Activity of the cefotaxime (HR756) desacetyl metabolite compared with those of cefotaxime and other cephalosporins.

R Wise, P J Wills, J M Andrews, K A Bedford.   

Abstract

The desacetyl metabolite (DES) of cefotaxime (HR756) is formed in vivo to a significant extent. The in vitro activities of DES, the parent compound, and cefazolin, cefoxitin, and cefuroxime were compared against 70 bacterial isolates. DES was found to possess approximately 1/10th the activity of the parent compound against the common Enterobacteriaceae, but was somewhat more active than the other three compounds tested. DES had no useful activity against Pseudomonas aeruginosa and was less active than cefotaxime or cefoxitin against Staphylococcus aureus or Bacteroides fragilis. Because DES may accumulate in renal failure or be concentrated in the biliary tract, its antimicrobial activity may have considerable clinical significance.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7352752      PMCID: PMC283730          DOI: 10.1128/AAC.17.1.84

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  4 in total

1.  Activity of HR 756 against Haemophilus influenzae, Bacteroides fragilis and Gram-negative rods.

Authors:  F A Drasar; W Farrell; A J Howard; C Hince; T Leung; J D Williams
Journal:  J Antimicrob Chemother       Date:  1978-09       Impact factor: 5.790

2.  Cefotoxime (HR 756) a new cephalosporin with exceptional broad-spectrum activity in vitro.

Authors:  J M Hamilton-Miller; W Brumfitt; A V Reynolds
Journal:  J Antimicrob Chemother       Date:  1978-09       Impact factor: 5.790

3.  HR 756, a highly active cephalosporin: comparison with cefazolin and carbenicillin.

Authors:  R Wise; T Rollason; M Logan; J M Andrews; K A Bedford
Journal:  Antimicrob Agents Chemother       Date:  1978-12       Impact factor: 5.191

4.  Novel method for detection of beta-lactamases by using a chromogenic cephalosporin substrate.

Authors:  C H O'Callaghan; A Morris; S M Kirby; A H Shingler
Journal:  Antimicrob Agents Chemother       Date:  1972-04       Impact factor: 5.191

  4 in total
  27 in total

1.  Infections in gynaecology and obstetrics and cefotaxime.

Authors:  E E Petersen
Journal:  Infection       Date:  1989 Nov-Dec       Impact factor: 3.553

2.  Penetration of cefotaxime into respiratory secretions.

Authors:  R B Fick; M R Alexander; R A Prince; J E Kasik
Journal:  Antimicrob Agents Chemother       Date:  1987-05       Impact factor: 5.191

3.  Comparison of in vitro activity of cefotaxime and desacetylcefotaxime alone and in combination against 320 gram-negative clinical isolates.

Authors:  G Piédrola; I Galan; A Leyva; M C Maroto
Journal:  Drugs       Date:  1988       Impact factor: 9.546

4.  The pharmacokinetics of cefotaxime and ceftriaxone in renal and hepatic dysfunction.

Authors:  R Wise; N Wright
Journal:  Infection       Date:  1985       Impact factor: 3.553

5.  Clinical experience with cefotaxime for the therapy of bacteremias due to gram-positive organisms.

Authors:  C J Schleupner
Journal:  Infection       Date:  1985       Impact factor: 3.553

6.  Cefotaxime monotherapy of bacterial meningitis caused by gram-positive pathogens.

Authors:  H F Helwig
Journal:  Infection       Date:  1985       Impact factor: 3.553

7.  Therapeutic activities of cefazolin, cefotaxime, and ceftazidime against experimentally induced Klebsiella pneumoniae pneumonia in rats.

Authors:  I A Bakker-Woudenberg; J C van den Berg; M F Michel
Journal:  Antimicrob Agents Chemother       Date:  1982-12       Impact factor: 5.191

8.  Comparative beta-lactamase hydrolysis of and inhibition by 7-aminothiazolyl alpha-methoxyimino cephalosporins.

Authors:  R N Jones; H W Wilson
Journal:  Infection       Date:  1982 Sep-Oct       Impact factor: 3.553

9.  The cooperation of cefotaxime and desacetyl-cefotaxime with respect to antibacterial activity and beta-lactamase stability.

Authors:  M Limbert; G Seibert; E Schrinner
Journal:  Infection       Date:  1982       Impact factor: 3.553

10.  In vitro activity of desacetylcefotaxime and the interaction with its parent compound, cefotaxime.

Authors:  K Oizumi; I Hayashi; S Aonuma; K Konno
Journal:  Drugs       Date:  1988       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.